Clinical Trial SuccessPhase 3 trial data showed that PEMGARDA provided significant protection against symptomatic COVID-19, demonstrating a substantial risk reduction compared to a placebo.
Market PotentialThere is belief in a market for an active monoclonal antibody against COVID given the unmet need among moderate-to-severe immunocompromised individuals.
Regulatory ProgressThe FDA updated the PEMGARDA Fact Sheet to include accurate data on its antiviral activity, which could restore confidence in the product.